August 22, 2013:The company expects to incur personnel-related restructuring charges of approximately $2.2 million in the third quarter of 2013. The net cash burn of approximately $17 million for the first half of 2013 was slightly below the projected range of $18 million to $20 million. Vical had cash and investments of approximately $70 million at June 30, 2013. The company is projecting net cash burn for the second half of 2013, including anticipated cash severance payments in connection with the restructuring, of $13 million to $15 million. The company believes its currently available cash and investments will be adequate to satisfy its needs at least through 2015."
yes, and meanwhile we will se interim efficacy results from Astellas CMV PIII concerning the first part of 100 patients. If positive we will see a much higher PPS. On top of this we will have the first results of Herpes PI / PII in mid Q3 2014, as this study monitors its patients for overall 7 months (2 months monitoring of virus shedding before vaccination, 3 months with vaccination and another 2 months afterwards) and recruitment will beginn in the next months and there is no lack of suitable patients. So the study will be filled with patients in short time.